Literature DB >> 10629052

Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.

M Chen1, A Cheng, F Candotti, Y J Zhou, A Hymel, A Fasth, L D Notarangelo, J J O'Shea.   

Abstract

The structure of Janus kinases (JAKs) is unique among protein tyrosine kinases in having tandem, nonidentical kinase and pseudokinase domains. Despite its conservation in evolution, however, the function of the pseudokinase domain remains poorly understood. Lack of JAK3 expression results in severe combined immunodeficiency (SCID). In this study, we analyze two SCID patients with mutations in the JAK3 pseudokinase domain, which allows for protein expression but disrupts the regulation of the kinase activity. Specifically, these mutant forms of JAK3 had undetectable kinase activity in vitro but were hyperphosphorylated both in patients' Epstein-Barr virus-transformed B cells and when overexpressed in COS7 cells. Moreover, reconstitution of cells with these mutants demonstrated that, although they were constitutively phosphorylated basally, they were unable to transmit cytokine-dependent signals. Further analysis showed that the isolated catalytic domain of JAK3 was functional whereas either the addition of the pseudokinase domain or its deletion from the full-length molecule reduced catalytic activity. Through coimmunoprecipitation of the isolated pseudokinase domain with the isolated catalytic domain, we provide the first evidence that these two domains interact. Furthermore, whereas the wild-type pseudokinase domain modestly inhibited kinase domain-mediated STAT5 phosphorylation, the patient-derived mutants markedly inhibited this phosphorylation. We thus conclude that the JAK3 pseudokinase domain is essential for JAK3 function by regulating its catalytic activity and autophosphorylation. We propose a model in which this occurs via intramolecular interaction with the kinase domain and that increased inhibition of kinase activity by the pseudokinase domain likely contributes to the disease pathogenesis in these two patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629052      PMCID: PMC85212          DOI: 10.1128/MCB.20.3.947-956.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

Review 1.  Jaks and STATs: biological implications.

Authors:  W J Leonard; J J O'Shea
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

2.  Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

Authors:  S Y Park; K Saijo; T Takahashi; M Osawa; H Arase; N Hirayama; K Miyake; H Nakauchi; T Shirasawa; T Saito
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

3.  Defective lymphoid development in mice lacking Jak3.

Authors:  T Nosaka; J M van Deursen; R A Tripp; W E Thierfelder; B A Witthuhn; A P McMickle; P C Doherty; G C Grosveld; J N Ihle
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

Review 4.  Signaling through the hematopoietic cytokine receptors.

Authors:  J N Ihle; B A Witthuhn; F W Quelle; K Yamamoto; O Silvennoinen
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.

Authors:  Y J Zhou; E P Hanson; Y Q Chen; K Magnuson; M Chen; P G Swann; R L Wange; P S Changelian; J J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

6.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).

Authors:  P Macchi; A Villa; S Giliani; M G Sacco; A Frattini; F Porta; A G Ugazio; J A Johnston; F Candotti; J J O'Shea
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

7.  Jak-STAT signaling induced by the v-abl oncogene.

Authors:  N N Danial; A Pernis; P B Rothman
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

8.  Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.

Authors:  J A Johnston; C M Bacon; D S Finbloom; R C Rees; D Kaplan; K Shibuya; J R Ortaldo; S Gupta; Y Q Chen; J D Giri
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

9.  Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3.

Authors:  D C Thomis; C B Gurniak; E Tivol; A H Sharpe; L J Berg
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

10.  Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

Authors:  S M Russell; N Tayebi; H Nakajima; M C Riedy; J L Roberts; M J Aman; T S Migone; M Noguchi; M L Markert; R H Buckley; J J O'Shea; W J Leonard
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  35 in total

Review 1.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.

Authors:  T C Yeh; E Dondi; G Uze; S Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 3.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

4.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

5.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

Review 6.  Titin/connectin-related proteins in C. elegans: a review and new findings.

Authors:  Tracey M Ferrara; Denise B Flaherty; Guy M Benian
Journal:  J Muscle Res Cell Motil       Date:  2005       Impact factor: 2.698

Review 7.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 9.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients.

Authors:  C John Sperati; Rulan S Parekh; Yvette Berthier-Schaad; Bernard G Jaar; Laura Plantinga; Nancy Fink; Neil R Powe; Michael W Smith; Josef Coresh; W H Linda Kao
Journal:  Am J Kidney Dis       Date:  2009-03-12       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.